Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Prostate Cancer
Clinical trial register · United States · industry-sponsored

Prostate Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 45 Florida 38 Illinois 25 Arizona 24 Georgia 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Pfizer4 Novartis Pharmaceuticals4 Lantheus Medical Imaging3 Janux Therapeutics3
State
California45 Florida38 Illinois25 Arizona24 Georgia19
All 38 states
Target enrolment
to

Prostate Cancer trials in the USA

72 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Lantheus Medical Imaging
Phase 2/3
408
Michigan
2026-09-30
Recruiting
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
NCT07813637Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
DrugJANX007
Janux Therapeutics
Phase 1
110
Tennessee
2026-09-10
Recruiting
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Not yet open
Mochida Medical USA, Inc.
Phase 1/2
30
New York
2026-08-01
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08
Active, closed
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
NCT06906471Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
Antelope Surgical Solutions, Inc
Phase 1/2
10
Florida, New York
2026-07-01
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Massachusetts, Michigan, Nebraska
2026-06-17
Recruiting
Francis Medical Inc.
Observational
2,500
Louisiana, Minnesota, Texas, Virginia
2026-06-05
Recruiting
Bayer
Observational
3,000
New Jersey
2026-06-04
Recruiting
Wren Laboratories LLC
Observational
1,500
Connecticut
2026-04-15
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Active, closed
AstraZeneca
Phase 1/2
6
California, Tennessee
2026-01-27
Recruiting
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Stratagen Bio, Inc.
Not applicable
75
New York, Virginia
2025-09-24
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Florida, Tennessee, Texas
2025-08-25
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina
2025-08-19
Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
DrugIlluccix
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2025-07-01
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Drug64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Recruiting
SURGE Therapeutics
Phase 1
18
Arizona, Florida
2025-05-08
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
SpectraCure AB
Phase 1/2
43
New York
2025-01-06
Active, closed
AIQ Solutions
Not applicable
25
New York, Texas
2024-12-02
Recruiting
Amgen
Phase 1
40
California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin
2024-11-25
Recruiting
Palette Life Sciences, Inc.
Not applicable
84
Arizona, California, Florida, Georgia, Massachusetts, New Jersey, Ohio, Pennsylvania
2024-10-31
Active, closed
Boston Scientific Corporation
Not applicable
230
California, Florida, Georgia, Illinois, Kansas, New York, Ohio, Pennsylvania
2024-10-30
Recruiting
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT06511141Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
Axonics, Inc.
Not applicable
150
Alabama, Arizona, California, Florida, Louisiana, Maryland, Michigan, Minnesota
2024-10-22
Active, closed
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
50
Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington
2024-09-23
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Active, closed
Complement Theory Inc.
Not applicable
146
Delaware
2024-05-12
Active, closed
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151Prostate Cancer, Prostate Adenocarcinoma
Curium US LLC
Phase 3
439
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Iowa
2024-04-01
Active, closed
Lantheus Medical Imaging
Phase 4
274
Alabama, California, Georgia, Iowa, Maryland, Massachusetts, Michigan, Missouri
2024-02-08
Recruiting
Clarity Pharmaceuticals Ltd
Phase 3
383
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kansas
2023-12-21
Active, closed
Novartis Pharmaceuticals
Phase 1
33
Minnesota
2023-11-07
Active, closed
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase 2/3
600
Maryland
2023-08-18
Recruiting
Novartis Pharmaceuticals
Phase 4
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-08-14
Active, closed
Lantheus Medical Imaging
Observational
500
Alabama, Arkansas, California, Michigan, Missouri, Nebraska, Pennsylvania, Tennessee
2023-05-22
Active, closed
Francis Medical Inc.
Not applicable
400
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Minnesota
2023-05-16
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
DrugsKeytruda·Pembrolizumab
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
132
California, Massachusetts, Missouri, Pennsylvania
2023-04-13
Active, closed
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
NCT05696444Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
Medtronic - MITG
Not applicable
144
California, Illinois, New York, North Carolina, Ohio, Washington
2022-12-14
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
DrugsJANX007·Darolutamide
Janux Therapeutics
Phase 1
272
Alabama, Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota
2022-09-15
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Florida, Georgia, Nebraska, New York
2022-07-20
Active, closed
AstraZeneca
Phase 3
1,035
Arizona, California, Colorado, Maryland, Minnesota, New Jersey, New York, Ohio
2022-03-25
Active, closed
Boston Scientific Corporation
Not applicable
500
Florida, Kansas, Michigan, New Jersey, Pennsylvania, South Carolina
2021-12-21
Recruiting
PSMA-PET to Guide Prostatectomy
NCT05381103Prostate Cancer
Five Eleven Pharma, Inc.
Phase 2/3
288
Indiana
2021-10-01
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
DrugsPRL-02·Enzalutamide·Prednisone·Dexamethasone
Astellas Pharma Global Development, Inc.
Phase 1
174
Arizona, California, Florida, Indiana, Kansas, Maryland, Nebraska, New Jersey
2021-06-14
Active, closed
Pfizer
Phase 3
599
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-05-12
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
Tempus AI
Observational
1,000
Texas
2020-10-19
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsAtirmociclib·Midazolam
Pfizer
Phase 2
362
California, Connecticut, Massachusetts, Michigan, Tennessee, Texas
2020-09-23
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
California, Colorado, Illinois, Michigan, New York, North Carolina, Tennessee
2020-07-01
Active, closed
Myriad Genetic Laboratories, Inc.
Observational
500
Alabama, California, Florida, Illinois, Maryland, Tennessee
2020-04-30
Recruiting
Amgen
Phase 1
479
California, Colorado, Connecticut, Georgia, Indiana, Kansas, Louisiana, Missouri
2020-03-04
Active, closed
Bayer
Observational
805
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2020-01-30
Active, closed
InSightec
Not applicable
14
California, Florida, Massachusetts, Minnesota, New York
2019-12-19
Active, closed
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT03957252Prostate Cancer, Prostate Cancer Screening, Performance Assessment of Novel Test
Nanostics
Observational
2,800
Maryland
2019-06-06
Active, closed
Eli Lilly and Company
Phase 2/3
393
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Massachusetts
2018-11-26
Active, closed
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
NCT03444844Prostate Cancer Recurrent, Prostate Cancer
Five Eleven Pharma, Inc.
Phase 1/2
60
Indiana
2018-05-10
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Indiana
2016-12-22
Active, closed
HALO Diagnostics
Observational
1,000
California
2016-05
Active, closed
Candel Therapeutics, Inc.
Phase 2
187
Colorado, Illinois, Louisiana, Maryland, Missouri, Nevada, New Jersey, New York
2016-05
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2015-11-27
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Active, closed
Candel Therapeutics, Inc.
Phase 3
711
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana, Maryland
2011-09
Rows per page Showing 1–72 of 72
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/prostate-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 72 of those studies listing the condition Prostate Cancer.

How many Prostate Cancer trials are recruiting in the US?

36 of the 72 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 34 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Prostate Cancer), 72 studies
PhaseStudiesRecruitingShare
Phase 1141119.4%
Phase 313618.1%
Not applicable11415.3%
Phase 1/211515.3%
Observational10313.9%
Phase 2526.9%
Phase 2/3536.9%
Phase 4324.2%

Most active sponsors

Lead sponsors with the most studies (Prostate Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca62
Novartis Pharmaceuticals43
Pfizer41
Amgen32
Astellas Pharma Global Development, Inc.32
Janux Therapeutics33
Lantheus Medical Imaging31
Bayer21
Boston Scientific Corporation20
Candel Therapeutics, Inc.20

Top states

Top states (Prostate Cancer), by number of studies with a site there
StateStudies
California45
Florida38
Illinois25
Arizona24
Colorado19
Georgia19
New York18
Indiana17
Alabama14
Maryland14
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.